Terms: = Liver cancer AND MDM4, DKFZp781B1423, 4194, ENSG00000198625, RP11-430C7_1, MRP1, MDMX, MGC132766 AND Prognosis
10363 results:
1. Predicting effect of anti-PD-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract] [Full Text] [Related]
2. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
3. Construction and validation of "WCH-nomogram" for predicting the prognosis after resection of colorectal liver metastases.
Jiang C; Liu W; Jin Z; Lan L; Xu L; Du A; Peng S; Zeng Y; Wang H; Liao M; Zhou J
Cancer Med; 2024 May; 13(9):e7222. PubMed ID: 38698687
[TBL] [Abstract] [Full Text] [Related]
4.
Waziri P; Auta R; Imam MU; Chindo BA; Ladan Z; Mohammed Z; Wayah S; Mohammed J; Tahir MI; Ahmad AE; Alhassan Y; Tyoapine D; Agbaji AS
J Evid Based Integr Med; 2024; 29():2515690X241251558. PubMed ID: 38689490
[TBL] [Abstract] [Full Text] [Related]
5. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract] [Full Text] [Related]
6. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
7. [Clinical Application of Microwave Ablation in Potentially Resectable Colorectal cancer With Simultaneously Multiple liver Metastases].
Han L; Wu XL; Guo F; Xi YN; Chang XY; Zhang CZ; Zhang JF; Ma PC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):161-168. PubMed ID: 38686711
[TBL] [Abstract] [Full Text] [Related]
8. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract] [Full Text] [Related]
9. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY; Zhu Y; Xie SZ; Qin LX
J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
[TBL] [Abstract] [Full Text] [Related]
10. Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway.
Zhao C; Zheng L; Ma Y; Zhang Y; Yue C; Gu F; Niu G; Chen Y
Int J Immunopathol Pharmacol; 2024; 38():3946320241249445. PubMed ID: 38679570
[TBL] [Abstract] [Full Text] [Related]
11. The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat liver Resection.
Gon H; Komatsu S; Omiya S; Kido M; Fukushima K; Urade T; Yoshida T; Arai K; Ishida J; Nanno Y; Tsugawa D; Yanagimoto H; Toyama H; Fukumoto T
Anticancer Res; 2024 May; 44(5):2031-2038. PubMed ID: 38677757
[TBL] [Abstract] [Full Text] [Related]
12. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract] [Full Text] [Related]
13. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
14. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study.
Dai J; He B; Zhang Y; Zhang H; Hu X; Xu L; Ni Y; Zhang X; Sun G; Zeng H; Shen P; Liu Z
World J Urol; 2024 Apr; 42(1):259. PubMed ID: 38662226
[TBL] [Abstract] [Full Text] [Related]
15. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
[TBL] [Abstract] [Full Text] [Related]
16. Identification and validation of a novel predictive signature based on hepatocyte-specific genes in hepatocellular carcinoma by integrated analysis of single-cell and bulk RNA sequencing.
He Y; Qi W; Xie X; Jiang H
BMC Med Genomics; 2024 Apr; 17(1):103. PubMed ID: 38654290
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
Wei M; Lu L; Luo Z; Ma J; Wang J
BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
[TBL] [Abstract] [Full Text] [Related]
18. Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α.
Zhao R; Cheng S; Bai X; Zhang D; Fang H; Che W; Zhang W; Zhou Y; Duan W; Liang Q; Xiao L; Nie G; Hou Y
Biotechnol J; 2024 Apr; 19(4):e2400050. PubMed ID: 38651271
[TBL] [Abstract] [Full Text] [Related]
19. m
Wu Y; Li L; Wang L; Zhang S; Zeng Z; Lu J; Wang Z; Zhang Y; Zhang S; Li H; Chen T
BMC Cancer; 2024 Apr; 24(1):506. PubMed ID: 38649860
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic impact of CD68+ tumor-associated macrophages in hepatocellular carcinoma: A meta-analysis.
Jin D; Qian L; Chen J; Yu Z; Dong J
Medicine (Baltimore); 2024 Apr; 103(16):e37834. PubMed ID: 38640338
[TBL] [Abstract] [Full Text] [Related]
[Next]
